Joaquín Martínez Head of Clinical Research Unit
T +34 917 328 000 (Ext )
jmartinezl@ext.cnio.es

The Haematological Malignancies Clinical Research Unit focuses on 3 main objectives:

• Molecular research of haematological cancers: studying of cancer induced changes at the proteomic and genomic levels. We aim to: i) find new genomic and proteomics biomarkers for a better diagnosis of these haematological diseases; ii) detect new molecular alterations as predictors of response to a treatment, for example by studying minimal residual disease; and iii) study immune mechanisms of cancer control, with a special focus on NK cells.
• In vitro & in vivo research: i) to establish the effects of new anticancer molecules in in vitro models of the disease; ii) to determine the mechanisms of resistance to anticancer drugs.
• Clinical research: translate preclinical findings to the patients through a phase I clinical trials unit.

Publications

• Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom Macroglobulinemia.(2019)
  Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter ZR, Anderson KC, Treon SP, Munshi NC, Fulciniti M
  Clin Cancer Res 25, 369-377.
• Spectrum and functional validation of PSMB5 mutations in multiple myeloma.(2019)
  Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.
  Leukemia 33, 447-456.
• Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.(2019)
  Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Perez Oteyza J, Herrera P, Barragan E, Montesinos P, Garcia Vela JA, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R
  Haematologica 104, 288-296.
• Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.(2018)
  Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators
  Lancet Oncol 19, 747-757.
• A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.(2018)
  Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.
  Haematologica 103, 880-889.
• Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.(2018)
  Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.
  Haematologica 103, e544-e548.
• Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.(2018)
  Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM.
  J Hematol Oncol 11, 96-.
• Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.(2018)
  Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A
  Cancer Lett 422, 107-117.
• Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.(2018)
  Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J
  Oncotarget 9, 30936-.
• Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.(2018)
  Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudzinski M, Razny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jazdzewska E, Sainz J, Canzian F, Campa D.
  Br J Haematol 183, 375-384.
• nherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.(2018)
  Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudzinski M, Razny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jazdzewska E, Sainz J, Canzian F, Campa D.
  Br J Haematol 183, 375-384.
• Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.(2018)
  Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J.
  J Oncol Pharm Pract (in press).
• How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?(2018)
  Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodríguez R, Torres JM, Díaz-Almirón M, López-Collazo E, Martinez-Lopez J, Pérez-Martínez A.
  Transfusion 58, 1340-1347.
• Analytical and clinical validation of a novel in-house deep sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.(2017)
  Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ.
  Leukemia 31, 1446-1449.
• Functional role and therapeutic targeting of p21-activated kinase 4 in multiple mieloma.(2017)
  Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Bandi RL, Amodio N, Xu Y, Szalat RL, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC.
  Blood 129, 2233-2245.
• Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.(2017)
  Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C.
  Haematologica 102, 103-109.
• Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.(2017)
  Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A
  Clin Cancer Res 23, 5824-5835.
• A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.(2017)
  Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R.
  J Mol Diagn 19, 99-106.
• Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.(2017)
  Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology.
  Gene Chromosome Canc 56, 812-820.
• Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale.(2016)
  Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Paji? T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S
  Leukemia 30, 1844-1852.
• Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.(2016)
  Mateos MV, Martínez-Lopez J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J
  Blood 127, 420-425.
• Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.(2016)
  Leivas A, Perez-Martinez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martinez-Lopez J.
  Oncoimmunology 5, e1250051-.
• Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials.(2016)
  Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, Cristi-Montero C, Fiuza-Luces C, Pareja-Galeano H, Martínez-López J, Garatachea N, Lucia A
  Crit Rev Oncol Hematol 105, 118-126.
• hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.(2015)
  Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM
  Cancer Cell 28, 486-499.
• Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.(2015)
  Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C.
  Nat Communications 6, 7539-.
• Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.(2015)
  Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group.
  Blood 126, 858-862.
• Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial.(2015)
  Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, De la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF.
  Haematologica 100, 1096-1102.
• Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.(2015)
  San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA.
  Haematologica 100, 1334-1334.
• Treatment for patients with newly diagnosed multiple myeloma in 2015.(2015)
  Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R, San Miguel JF
  Blood Rev 29, 387-403.
• Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.(2015)
  Campa D1, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F
  Int J Cancer 136, E351-E358.
• Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.(2015)
  Rios R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Jerez-Cayuela A, W?tek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J
  Endocr-Relat Cancer 22, 545-559.
• CALR mutations screening should not be studied in splanchnic vein thrombosis.(2015)
  Castro N, Rapado I, Ayala R, Martinez-Lopez J
  Br J Haematol 170, 588-589.
• Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions.(2014)
  Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M
  New Engl J Med 370, 1101-1110.
• RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.(2014)
  Papaemmanuil E1, Rapado I2, Li Y1, Potter NE3, Wedge DC1, Tubio J1, Alexandrov LB1, Van Loo P4, Cooke SL1, Marshall J1, Martincorena I1, Hinton J1, Gundem G1, van Delft FW5, Nik-Zainal S1, Jones DR1, Ramakrishna M1, Titley I3, Stebbings L1, Leroy C1, Menzies A1, Gamble J1, Robinson B1, Mudie L1, Raine K1, O'Meara S1, Teague JW1, Butler AP1, Cazzaniga G6, Biondi A6, Zuna J7, Kempski H8, Muschen M9, Ford AM3, Stratton MR1, Greaves M10, Campbell PJ
  Nat Genet 46, 116-125.
• Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.(2014)
  Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M; InSiGHT
  Nat Genet 46, 107-115.
• Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.(2014)
  Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E
  J Clin Oncol 32, 1595-1604.
• Prognostic value of deep sequencing method for minimal residual disease detection in multiple mieloma.(2014)
  Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R
  Blood 123, 3073-3079.
• GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?(2014)
  Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF
  Blood 124, 1887-1893.
• Whole exome sequencing in splenic marginal 1 zone lymphoma reveals mutations in 2 genes involved in marginal zone differentiation.(2014)
  Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA
  Leukemia 28, 1334-1340.
• Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.(2014)
  Menezes J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV, Montes-Moreno S, Hernández-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Alvarez S, Cigudosa JC
  Leukemia 28, 823-829.
• Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.(2014)
  Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R
  Leukemia 28, 391-397.
• The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.(2014)
  Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM, Garcia-Gutierrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martinez-Lopez J, Arbelo E, Besses C
  Haematologica 99, e55-e57.
• Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.(2014)
  Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C, Lode' L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S
  Haematologica 99, e98-e101.
• Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations–an extensive replication of the associations from the candidate gene era.(2014)
  Martino A, Campa D, Jurczyszyn A, Martínez-López J, Moreno MJ, Varkonyi J, Dumontet C, García-Sanz R, Gemignani F, Jamroziak K, Stepiel A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudzinski M, Watek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Ríos R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F.
  Cancer Epidem Biomar 23, 670-674.